Your browser doesn't support javascript.
loading
Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression.
Gantenbein, Nadine; Bernhart, Eva; Anders, Ines; Golob-Schwarzl, Nicole; Krassnig, Stefanie; Wodlej, Christina; Brcic, Luka; Lindenmann, Joerg; Fink-Neuboeck, Nicole; Gollowitsch, Franz; Stacher-Priehse, Elvira; Asslaber, Martin; Gogg-Kamerer, Margit; Rolff, Jana; Hoffmann, Jens; Silvestri, Alessandra; Regenbrecht, Christian; Reinhard, Christoph; Pehserl, Anna-Maria; Pichler, Martin; Sokolova, Olga; Naumann, Michael; Mitterer, Valentin; Pertschy, Brigitte; Bergler, Helmut; Popper, Helmut; Sattler, Wolfgang; Haybaeck, Johannes.
Afiliación
  • Gantenbein N; Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria; Center for Biomarker Research in Medicine, Stiftingtalstrasse 5, 8010 Graz, Austria.
  • Bernhart E; Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Molecular Biology and Biochemistry, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria.
  • Anders I; Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria.
  • Golob-Schwarzl N; Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria; Center for Biomarker Research in Medicine, Stiftingtalstrasse 5, 8010 Graz, Austria.
  • Krassnig S; Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria.
  • Wodlej C; Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria; Center for Biomarker Research in Medicine, Stiftingtalstrasse 5, 8010 Graz, Austria.
  • Brcic L; Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria.
  • Lindenmann J; Division of Thoracic and Hyperbaric Surgery, Medical University of Graz, Auenbruggerplatz 29, 8036 Graz, Austria.
  • Fink-Neuboeck N; Division of Thoracic and Hyperbaric Surgery, Medical University of Graz, Auenbruggerplatz 29, 8036 Graz, Austria.
  • Gollowitsch F; Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria.
  • Stacher-Priehse E; Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria.
  • Asslaber M; Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria.
  • Gogg-Kamerer M; Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria.
  • Rolff J; Experimental Pharmacology & Oncology Berlin GmbH-Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany.
  • Hoffmann J; Experimental Pharmacology & Oncology Berlin GmbH-Berlin-Buch, Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany.
  • Silvestri A; Cpo - Cellular Phenomics & Oncology Berlin-Buch GmbH, Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany.
  • Regenbrecht C; Cpo - Cellular Phenomics & Oncology Berlin-Buch GmbH, Robert-Rössle-Str. 10, 13125 Berlin-Buch, Germany.
  • Reinhard C; Eli Lilly & Company, Lilly Corporate Center, 46285 Indiana, Indianapolis, USA.
  • Pehserl AM; Division of Oncology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.
  • Pichler M; Division of Oncology, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.
  • Sokolova O; Institute of Experimental Internal Medicine, Otto-von-Guericke-University Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany.
  • Naumann M; Institute of Experimental Internal Medicine, Otto-von-Guericke-University Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany.
  • Mitterer V; Institute of Molecular Biosciences, Karl-Franzens-University of Graz, Humboldtstraße 50, 8010 Graz, Austria.
  • Pertschy B; Institute of Molecular Biosciences, Karl-Franzens-University of Graz, Humboldtstraße 50, 8010 Graz, Austria.
  • Bergler H; Institute of Molecular Biosciences, Karl-Franzens-University of Graz, Humboldtstraße 50, 8010 Graz, Austria.
  • Popper H; Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria.
  • Sattler W; Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Molecular Biology and Biochemistry, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria.
  • Haybaeck J; Diagnostic and Research Institute of Pathology, Medical University of Graz, Neue Stiftingtalstrasse 6, 8010 Graz, Austria; Center for Biomarker Research in Medicine, Stiftingtalstrasse 5, 8010 Graz, Austria; Department of Pathology, Medical Faculty, Otto-von-Guericke-University Magdeburg, Leipziger
Eur J Cancer ; 101: 165-180, 2018 09.
Article en En | MEDLINE | ID: mdl-30077122
ABSTRACT
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide. Dysregulation of protein synthesis plays a major role in carcinogenesis, a process regulated at multiple levels, including translation of mRNA into proteins. Ribosome assembly requires correct association of ribosome subunits, which is ensured by eukaryotic translation initiation factors (eIFs). eIFs have become targets in cancer therapy studies, and promising data on eIF6 in various cancer entities have been reported. Therefore, we hypothesised that eIF6 represents a crossroad for pulmonary carcinogenesis. High levels of eIF6 are associated with shorter patient overall survival in adenocarcinoma (ADC), but not in squamous cell carcinoma (SQC) of the lung. We demonstrate significantly higher protein expression of eIF6 in ADC and SQC than in healthy lung tissue based on immunohistochemical data from tissue microarrays (TMAs) and on fresh frozen lung tissue. Depletion of eIF6 in ADC and SQC lung cancer cell lines inhibited cell proliferation and induced apoptosis. Knockdown of eIF6 led to pre-rRNA processing and ribosomal 60S maturation defects. Our data indicate that eIF6 is upregulated in NSCLC, suggesting an important contribution of eIF6 to the development and progression of NSCLC and a potential for new treatment strategies against NSCLC.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Factores Eucarióticos de Iniciación / Neoplasias Pulmonares Límite: Aged / Female / Humans / Male Idioma: En Revista: Eur J Cancer Año: 2018 Tipo del documento: Article País de afiliación: Austria

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Factores Eucarióticos de Iniciación / Neoplasias Pulmonares Límite: Aged / Female / Humans / Male Idioma: En Revista: Eur J Cancer Año: 2018 Tipo del documento: Article País de afiliación: Austria